Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Other Non-Current Assets: 2020-2025

Historic Other Non-Current Assets for Legend Biotech (LEGN) over the last 4 years, with Sep 2025 value amounting to $11.0 million.

  • Legend Biotech's Other Non-Current Assets rose 468.84% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 468.84%. This contributed to the annual value of $6.1 million for FY2024, which is 305.63% up from last year.
  • Per Legend Biotech's latest filing, its Other Non-Current Assets stood at $11.0 million for Q3 2025, which was up 94.20% from $5.7 million recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Other Non-Current Assets peaked at $24.6 million during Q1 2022, and registered a low of $3,983 during Q1 2021.
  • Moreover, its 3-year median value for Other Non-Current Assets was $1.6 million (2024), whereas its average is $3.5 million.
  • Per our database at Business Quant, Legend Biotech's Other Non-Current Assets surged by 618,102.36% in 2022 and then tumbled by 95.69% in 2023.
  • Over the past 5 years, Legend Biotech's Other Non-Current Assets (Quarterly) stood at $5.1 million in 2021, then slumped by 71.11% to $1.5 million in 2022, then rose by 0.40% to $1.5 million in 2023, then spiked by 305.63% to $6.1 million in 2024, then surged by 468.84% to $11.0 million in 2025.
  • Its last three reported values are $11.0 million in Q3 2025, $5.7 million for Q2 2025, and $5.6 million during Q1 2025.